MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,265,494
EPS
-$1.19
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development expenses
649,877
1,809,209
1,432,138.25*
1,661,646
General and administrative expenses
1,686,261
1,522,005
1,182,127*
1,827,197
Operating loss
-2,336,138
-3,331,214
-2,614,265.25*
-3,488,843
Other income
-
-
5,000*
-
Unrealized loss on digital assets
768,348
59,824
-
-
Unrealized gain on digital assets at fair value
-
-
73,795*
-
Realized loss on digital assets
159,005
-
-
-
Interest and dividend income, net
-
13,859
27,372.75*
-
Interest (expense) income, net
-2,003
-
-
-
Other income, net
-
-
-
52,270
Net operating loss before income tax benefit
-
-3,377,179
-2,508,097.5
-
Total other income expenses
-929,356
-
-
-
Net loss
-3,265,494
-3,377,179
-2,508,097.5
-3,436,573
Basic EPS
-1.19
-1.29
-1.916
-0.07
Diluted EPS
-1.19
-1.29
-1.916
-0.07
Basic Average Shares
2,750,742
2,623,143
1,309,271*
47,525,522
Diluted Average Shares
2,750,742
2,623,143
1,309,271*
47,525,522
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$3,265,494
(16.99%↑ Y/Y)
Operating loss
-$2,336,138
(40.87%↑ Y/Y)
Total other income
expenses
-$929,356
General and
administrative expenses
$1,686,261
(12.16%↑ Y/Y)
Research and development
expenses
$649,877
(-73.44%↓ Y/Y)
Unrealized loss on digital
assets
$768,348
Realized loss on digital
assets
$159,005
Interest (expense)
income, net
-$2,003
Buy us a coffee
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)